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The effect of E-series prostaglandins (PGE) on hepatic glucose metabolism is controversial. This study uses 
isolated rat hepatocytes and exogenously added PGE analogs or frequent native PGE additions (to 
compensate for hepatic PGE degradation) to define PGE’s effect on hepatic glycogenolysis. 16,16-Dimethyl 
PGE2, lS(S),15-methyl PGE2, PGEl and PGE2 all inhibit glucagon-stimulated glycogenolysis. It is 
concluded that E-series prostaglandins can act directly on the liver to inhibit glycogenolysis. 
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1. INTRODUCTION 
Prostaglandins are recognized to play a regula- 
tory role in a variety of tissues, but their action on 
hepatic glucose metabolism remains controversial. 
In vivo studies using prostaglandin infusions or 
prostaglandin synthesis inhibitors have generally 
supported a hyperglycemic effect of E-series pros- 
taglandins (PGE) [l-4], resulting from increased 
hepatic glucose output [3]. In contrast, in vitro 
studies demonstrate no effect [5-71 or inhibition 
[8] by PGE of hepatic glucose production. In part, 
these discrepancies can be understood by recogni- 
tion that in vivo PGE can alter circulating hor- 
mone levels [9- 111, and in vitro is rapidly meta- 
bolized by liver [ 12-141. 
hepatocytes, synthetic PGE analogs as well as 
multiple additions of natural PGEs were used. The 
study demonstrates that PGE inhibits glucagon- 
stimulated glycogenolysis, consistent with its re- 
ported effects on CAMP accumulation. 
2. MATERIALS AND METHODS 
2. I. Hepatocyte isolation 
Recently, authors in [15,16] reported that PGE 
can inhibit glucagon-stimulated hepatocyte CAMP 
production. Also, those in [ 171 demonstrated PGE- 
induced desensitization of hepatic adenylate cyclase 
to glucagon stimulation. Based on these observa- 
tions, the present study was designed to define the 
effect of PGE on glucagon-stimulated glycogeno- 
lysis. Studies were performed in suspended, iso- 
lated hepatocytes to avoid possible secondary 
influences of PGE seen in vivo. Additionally, to 
compensate for the rapid metabolism of PGE by 
Hepatocytes were isolated using a modification 
of the collagenase perfusion technique in [18]. All 
experiments were initiated at 7 : 30 a.m. Male, fed, 
Sprague-Dawley rats (270-320 g) were anesthe- 
tized with pentobarbital (So-100 mg/kg intraperi- 
toneally). The liver was perfused through the por- 
tal vein with bicarbonate buffer [116 mM NaCl, 
6mM KCl, 0.6mM MgS04, 0.74mM KH2P04, 
12 mM NaHCOs, 15 mM glucose (pH 7.1-7.4), 
37”C, equilibrated with 95% 02/5% COZ] for 
10min while the liver was isolated. The liver was 
then placed in a recirculating perfusion chamber, 
and collagenase (40 mg/lOO ml) and CaC12 (1 mM 
final concentration) were added to the perfusion 
medium. This perfusion was continued for 15 min, 
after which the liver cells were carefully dispersed 
in fresh perfusion buffer. Cells were filtered and 
washed 3 times at 65 x gin a wash buffer [128.5 mM 
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NaCI, 5.2mM KCI, 0.9mM Mg Sod, 0.12 mM 
CaC12,3 mMNazHP04,5.0mMglucose(pH7.35)]. 
Cells were finally resuspended in incubation buffer 
[wash buffer plus 10mM Tris, 1 mM CaCl2 
(pH 7.4)]. Hepatocyte quality was determined by 
trypan-blue exclusion and glucagon-stimulated 
glucose output. All preparations were at least 85% 
viable (91 + 3%, mean + SD, n = 13) on the basis 
of trypan-blue exclusion, and demonstrated in- 
creased glucose output over basal of at least 40% in 
the presence of 5 x lo-’ M glucagon (see section 3). 
2.2. Incubations 
All incubations were conducted at 37°C in a 
shaking incubator bath continuously gassed with 
95% 02/5% CO2. Cells (2.5-5.0 x 106ml) were 
suspended in incubation buffer and pre-incubated 
at 37°C for 30min. Glucagon or prostaglandins 
were added at time zero or as indicated. Incubation 
aliquots were placed on ice and reactions ter- 
minated by rapid centrifugation. Dilvent used to 
dissolve prostaglandins contained trace amounts 
of ethanol. Addition of diluent alone to hepatocyte 
incubations caused no change in any parameters 
measured. 
2.3. Glycogenolysis 
Glycogenolysis was estimated by the rate of glu- 
cose appearance in the incubation as no gluconeo- 
genie substrates were added [19]. Glucose was 
measured using a glucose oxidase method [20]. In- 
cubation glucose content was determined at 0, 10, 
20 and 30 min of incubation, and the data expres- 
sed as pug glucose per lo6 cells. The rate of glyco- 
genolysis was concluded as the slope of a linear 
regression through these points and was propor- 
tional to cell concentrations over the range 
l-5 x lo6 cells/ml. 
2.4. Reagents 
All chemicals used were of reagent grade. Col- 
lagenase (type II) was obtained from Worthington 
Diagnostic Systems, Freehold, NJ. Glucagon was 
obtained from Eli Lilly and stored at -20°C in 
10niM NaOH. Prostaglandins were the gift of 
Dr J. Pike, Upjohn Pharmaceuticals, Kalamazoo, 
MI. 
2.5. Statistics 
Data were analyzed on a paired basis. Glucagon- 
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stimulated glycogenolysis was compared to simul- 
taneously incubated cells under basal conditions. 
Similarly, incubations including prostaglandins 
were compared to incubations, run simultaneously, 
excluding prostaglandins. ‘N’ refers to the number 
of separate incubations each run on separate hepa- 
tocyte preparations. Statistical significance was 
determined using Student’s t-test (paired form) 
with a single-tailed p < 0.05 considered significant. 
3. RESULTS AND DISCUSSION 
Basal and glucagon stimulated glycogenolysis 
were linear for the 30min observation period 
(fig.1). Glucagon (5 x lo-‘M) resulted in an 
average 175 + 76% stimulation over basal glucose 
output (basal 2.19 rt 0.41pg/106 cells per min, 
5 x lo-‘M glucagon 4.48 f 0.50/lg/106 cells per 
min, mean + SE, n = 9). Addition of the synthetic 
PGE analog, 16,16-dimethyl PGE2 inhibited gluca- 
gon-stimulated glycogenolysis (fig. 1) in a dose- 
dependent fashion (fig.2). As fig.2 indicates, 16,16- 
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Fig. 1. Hepatic glycogenolysis. Incubations as per text. 
Data are the mean f SE of 5 incubations; 2.5 x lo6 
hepatocytes/ml. Lines plotted represent least-square 
regressions. (0) Cells alone, (0) 5 x lo-‘M glucagon, 
(A) 5 x lo-‘M glucagon plus 8 x lo-‘M 16,16-dime- 
thy1 PGEz. 
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Fig.2. Inhibition of glucagon-stimulated glycogenolysis 
by 16,lddimethyl PGE2. Incubations as per text con- 
taining 2.5 x lo6 hepatocytes/ml. Data are presented as 
mean f SE. Values are expressed as percent of glyco- 
genolysis in the presence of 5 x lo-’ M glucagon alone 
(mean 100% value = 4.48 f 0.50, n = 9). Concentra- 
tions of 16,lddimethyl PGE2 indicated were added in 
addition to 5 x lo-‘M glucagon at time zero. Basal 
value represents glucose output in the absence of gluca- 
gon and without 16, lddimethyl PGE2 expressed as per- 
centage of glucagon (5 x lo-‘M) stimulated glucose 
production (mean basal glucose output = 2.19 f 0.41 pg 
glucose/106 cells per min, n = 9). 
dimethyl PGEz inhibited approx. two-thirds of the 
glucagon-stimulated glucose output. Addition of 
1.7 x 10e6M 16,16-dimethyl PGE2 alone did not 
affect basal glucose output (basal 1.93 + 0.79pg 
glucose/106 cells per min; basal + 16,16-dimethyl 
PGE2 1.97 f 0.73pg glucose/106 cells per min; 
n = 6; mean f SD, p > 0.05). Similarly, 10e6 M 
15(S),15-methyl PGEz inhibited glucagon-stimu- 
lated glycogenolysis to a level of 70 * 7% of 
lo-‘M glucagon alone (table 1). 
PGEi and PGE2 are metabolized by hepatocytes 
[12-141 with half-lives of approx. 5 min at 10e6 M 
[ 131. Based on these data, the effect of addition of 
3 x 10m9 mol PGEr or PGE2 every 10 min to a 3 ml 
hepatocyte incubation was studied. This protocol 
was adopted to maintain a concentration greater 
than lo-‘M over the entire incubation period. 
Added in this manner, PGEi and PGEz inhibited 
glucagon-stimulated glycogenolysis (table 1). 
These studies demonstrate that PGE can act 
directly on the hepatocyte to inhibit glucagon- 
Table 1 
Effect of PGE on glucagon-stimulated h patocyte 
glycogenolysis 
Conditions Glucose produc- 
tion (pg/106 
cells per min) 
Set I 
Basal (n = 5) 2.25 of: 1.23 
5 x lo-’ M glucagon 4.12 + 1.51 
5 x lo-’ M glucagon + 1.7 x 10m6M 
16, lddimethyl PGE2 2.74 f 1.35a 
Set II 
Basal (n = 3) 
lo-’ M glucagon 
lo-’ M glucagon + 10m6 M 
15(S),15-methyl PGE2 
2.20 * 1.97 
3.77 f 2.25 
2.79 + 1.64= 
Set III 
Basal (n = 5) 
lo-’ M glucagon 
lo-’ M glucagon + PGEi 
lo-’ M glucagon + PGE2 
2.46 f 1.92 
4.63 k 1.40 
3.16 k 0.96a 
2.66 + 1.42= 
Incubations as per text. Additions made at time zero 
except PGEr and PGE2 which were added at 0, 10 and 
20 min. “p < 0.05 as compared to addition of glucagon 
alone. Values, mean + SD 
stimulated glycogenolysis, consistent with its 
known effect on glucagon-stimulated CAMP pro- 
duction [ 15,161 and adenylate cyclase activity [ 171. 
This suggests that the hyperglycemic effect of PGE 
observed in vivo [l-4] may be secondary to PGE- 
induced hormonal changes, such as inhibition of 
insulin secretion [9] or stimulation of glucagon 
secretion [21]. Further the lack of reproducible in 
vitro hepatic PGE effects in the past may be ex- 
plained by failure to compensate for hepatic PGE 
metabolism [12-141 as well as failure to examine 
stimulated states of glycogenolysis pecifically. 
In liver membrane systems, PGE stimulates 
adenylate cyclase [22,23], however in the intact 
hepatocyte, PGE appears to act as an adenylate 
cyclase antagonist. Similar situations have been 
described in the renal medulla where PGE stimu- 
lates adanylate cyclase but inhibits the ability of 
ADH to stimulate cyclase [24], and in corpora 
lutea where PGFz~ inhibits leutenizing hormone- 
stimulated CAMP accumulation [25]. 
295 
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In summary, PGE can act on hepatocytes to in- 
hibit glucagon-stimulated glycogenolysis consis- 
tent with PGE’s effect on glucagon-stimulated 
hepatic adenylate cyclase. This suggests that pros- 
taglandins may play a physiologic role in modu- 
lating the action of hormones on the liver. 
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